ARG Collaborating with Cytokinetics on the COURAGE-ALS Trial of Reldesemtiv
Our partner Cytokinetics, Incorporated announced August 2, 2021 that COURAGE-ALS, a Phase 3 clinical trial of Reldesemtiv in patients with ALS, is open to enrollment.
Do You Have Visibility into Your CRO’s processes?
We are cost-conscious, financially responsible, and considerate of budgets, yet understand and clearly communicate how additional activities could add value and reduce time to market.
Xtalks Webinar: ALS Biomarkers in Drug Development
Atlantic Research Group will be presenting a webinar via Xtalks on Tuesday, June 22, 2021 at 11am EST. Please register here. Webinar Content Description: Amyotrophic…
Does Your CRO Value Every Single Patient?
Every patient counts. While large-scale intricately-designed studies can afford to lose patients, clinical trials for rare patient populations are not buffered for atrophy. ARG emphasizes that every patient is vital; in fact, we place the utmost importance on every data point in every study.
BPL And Atlantic Research Group Enter Into Long-term Collaboration
28 April, 2021–Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies headquartered in Elstree, UK, today announced the signing of a collaboration agreement…